Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 08, 2026 16:05 ET | Source: TheRas, Inc. (d/b/a BBOT)

BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers

BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patientsBBO-8520 monotherapy continues to show highly...
September 01, 2026 16:05 ET | Source: TheRas, Inc. (d/b/a BBOT)

BBOT to Participate in Upcoming Investor Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway...
August 11, 2026 16:40 ET | Source: TheRas, Inc. (d/b/a BBOT)

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway...
August 11, 2026 16:05 ET | Source: TheRas, Inc. (d/b/a BBOT)

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Continued to advance monotherapy and combination cohorts for all clinical programsInitiated dosing of BBO-11818 in combination with cetuximab and after the end of the quarter, initiated dosing of...
May 12, 2026 17:03 ET | Source: TheRas, Inc. (d/b/a BBOT)

BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programsAnnounced publication in Cancer Discovery highlighting preclinical data demonstrating...
May 12, 2026 16:05 ET | Source: TheRas, Inc. (d/b/a BBOT)

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway...
April 22, 2026 16:05 ET | Source: TheRas, Inc. (d/b/a BBOT)

BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026

BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potently suppressing MAPK signaling and inhibiting cell proliferation in KRAS-mutant cell lines BBO-11818...
April 22, 2026 09:00 ET | Source: TheRas, Inc. (d/b/a BBOT)

BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman

Pedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBOT, will assume the position of Chief Executive Officer, bringing his extensive drug development...
April 21, 2026 17:30 ET | Source: TheRas, Inc. (d/b/a BBOT)

BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026

BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the kinase activity of PI3Kα and with no observed...
April 20, 2026 16:06 ET | Source: TheRas, Inc. (d/b/a BBOT)

BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma

BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors Updated Phase 1 clinical data are...